The developing biotech sector in China

Richard Tadd Blog

Twenty years ago, China’s biotech industry was worth around $2.4bn. This year, its revenues are expected to exceed $1.2tn. That’s a remarkable achievement by any standards, and one that has understandably led to excitement among investors and industry professionals alike. How has it been achieved? How has the sector actually changed and what can we expect to see in the …

Promising Chinese Alzheimer’s drug to see $3bn investment over next 10 years

Richard Tadd Industry News

The Chinese pharmaceutical market sees another significant victory in recent weeks as it is announced that China has conditionally approved the first new Alzheimer’s drug to hit the global market in 17 years, and it will be distributed worldwide for long-term testing. The seaweed-derived drug GV-971, more colloquially known as Oligomannate, appears to improve cognition in patients with mild to …

Amgen finalises investment as Chinese biopharmaceuticals seem a strong prospect in 2020

Richard Tadd Industry News

The California-based multinational giant Amgen recently finalised an investment of $2.8 billion in Chinese pharmaceuticals, and it seems that the trends of the 2010s will continue as China continues to assert itself as a major player in the global biotechnology and pharmaceutical trades. Amgen itself has aggressively expanded its global influence since 2011, doubling its geographic presence from around 50 …